Topic Highlight
Copyright ©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Oct 21, 2014; 20(39): 14237-14245
Published online Oct 21, 2014. doi: 10.3748/wjg.v20.i39.14237
Table 1 Methods data of the three published meta-analyses on neo-adjuvant therapy in pancreatic carcinoma n (%)
YearnType studyMean age (yr)ChemotherapyAgents regimenRadiotherapyDose (Gy) IORT
Gillen et al[2]80-0911178P-33R62.5107 (96.4)5FU > GEM > Tax > Others44S + 48C104 (93.7)24-6313 (12.5)
Assifi et al[35]93-101414P-0RN/P14 (100)GEM > 5FU3S + 11C12 (85)30-500 (0)
Andriulli et al[36]97-082020P-0R63.020 (100)GEM > Cis13S + 7C17 (85)30-40N/P
Table 2 Results of the three published meta-analyses on neo-adjuvant therapy in pancreatic carcinoma in terms of safety (postoperative morbidity and toxicity) and efficacy (response and resection)
Response (%)
Resection (%)
Toxicity (%)CompletePartialProgressionResectedR0MonoCombinedPostoperative morbidity (%)
Gillen et al[2]01:26.33.630.620.973.660.480.966.226.7
02:31.34.830.220.833.226.227.333.039.1
Assifi et al[35]1:370.89.517.065.855.9N/PN/PN/P
02:46.24.031.821.831.619.6N/P
Andriulli et al[36]1:291215.081.266.4N/PN/PN/P
2:332732.026.416.0N/P
Table 3 Results of the three published meta-analyses on neo-adjuvant therapy in pancreatic carcinoma in terms of survival and mortality
Mean SurvivalMortalityEstimated survival (%)
(mo)(%)1-yr2-yr
Gillen et al[2]01:23.33.977.947.4
02:20.57.179.850.1
Assifi et al[35]01:15.1N/PN/PN/P
02:11.2
Andriulli et al[36]01:18.8N/P91.786.3
2:1467.254.2